Table 1.
Demographic and Clinical Characteristics of Sample.
| Variable | Value |
|---|---|
| Demographic | |
| Age, years, mean (SD) | 65.86 (6.87) |
| Race, n (%) | |
| White | 16 (72.73) |
| African American/Black | 4 (18.18) |
| Hispanic | 2 (9.09) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 3 (13.64) |
| Not Hispanic/Latino | 17 (77.27) |
| Not documented | 2 (9.09) |
| Disease characteristics | |
| Gleason, mean (SD) | 7.59 (0.91) |
| Clinical T-stage, n (%) | |
| T1c | 5 (22.72) |
| T2a | 6 (27.27) |
| T2b | 2 (9.09) |
| T2c | 5 (22.72) |
| T3a | 1 (4.55) |
| T3b | 1 (4.55) |
| Not documented | 2 (9.09) |
| Pre-EBRT clinical markers | |
| PSA (N° = 0–3.99 ng/ml), mean (SD) | 3.69 (5.24) |
| Testosterone (N° = 181–758 ng/dl), mean (SD) | 220.37 (166.02) |
| WBC (N° = 4.23–9.07 K/μl), mean (SD) | 6.13 (1.67) |
| RBC (N° = 4.63–6.08 M/μl), mean (SD) | 4.61 (0.44) |
| Hemoglobin (N° = 13.70–17.50 g/dl), median (range) | 13.95 (12.80–15.60) |
| Albumin (N° = 3.70–4.70 g/dl), median (range) | 4.10 (2.70–4.40) |
| BMI (N° = 18.50–24.90 kg/m2), median (range) | 29.85 (22.90–40.70) |
Note. N = 22. BMI = body mass index; EBRT = external beam radiation therapy; N° = normal ranges; PSA = prostate-specific antigen; RBC = red blood cell count; T-stage = tumor stage (TNM = primary tumor, lymph node, metastases, classification for tumor staging); WBC = white blood cell count.